Hudson Bay Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Hudson Bay Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07M	Buy	+2,000	New	+$1.02M	﹤0.01%	906
2025 Q2	–	Sell	-12,610	Closed	-$4.18M	–	1550
2025 Q1	$4.18M	Buy	+12,610	New	+$4.14M	0.01%	647
2023 Q2	–	Sell	-12,850	Closed	-$3.11M	–	931
2023 Q1	$3.11M	Buy	+12,850	New	+$3.5M	0.03%	425
2018 Q2	–	Sell	-45,000	Closed	-$5.26M	–	910
2018 Q1	$5.26M	Buy	45,000 +15,000	+50%	+$1.85M	0.11%	215
2017 Q4	$2.75M	Buy	+30,000	New	+$1.71M	0.06%	254

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Hudson Bay Capital Management's MDGL Position: Q2 2026 in Review

Hudson Bay Capital Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 2,000 shares worth $1.07M. The stake represents ﹤0.01% of the portfolio and ranks #906 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in MDGL as recently as Q1 2025.

Hudson Bay Capital Management first reported a position in MDGL in Q4 2017 and has held it in 5 quarters since. The position peaked at $5.26M in Q1 2018. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Hudson Bay Capital Management held 2,000 shares of Madrigal Pharmaceuticals worth $1.07M as of Q2 2026.
Madrigal Pharmaceuticals was a new Hudson Bay Capital Management position in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #906 holding.
Hudson Bay Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2017 and has held it in 5 quarters since.
Hudson Bay Capital Management's Madrigal Pharmaceuticals position peaked at $5.26M in Q1 2018.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.